Your browser doesn't support javascript.
loading
A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.
Doria-Rose, Nicole A; Georgiev, Ivelin; O'Dell, Sijy; Chuang, Gwo-Yu; Staupe, Ryan P; McLellan, Jason S; Gorman, Jason; Pancera, Marie; Bonsignori, Mattia; Haynes, Barton F; Burton, Dennis R; Koff, Wayne C; Kwong, Peter D; Mascola, John R.
Afiliação
  • Doria-Rose NA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
J Virol ; 86(15): 8319-23, 2012 Aug.
Article em En | MEDLINE | ID: mdl-22623764
Antibody PG9 is a prototypical member of a class of V1/V2-directed antibodies that effectively neutralizes diverse strains of HIV-1. We analyzed strain-specific resistance to PG9 using sequence and structural information. For multiply resistant strains, mutations in a short segment of V1/V2 resulted in gain of sensitivity to PG9 and related V1/V2 neutralizing antibodies, suggesting both a common mechanism of HIV-1 resistance to and a common mode of recognition by this class of antibodies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Proteína gp120 do Envelope de HIV / HIV-1 / Anticorpos Neutralizantes Limite: Humans Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Proteína gp120 do Envelope de HIV / HIV-1 / Anticorpos Neutralizantes Limite: Humans Idioma: En Ano de publicação: 2012 Tipo de documento: Article